Cargando…

Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

INTRODUCTION: Recent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Echinocandins, a new class of antifungal agents, are effective against resistant candidal species. As...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zilberberg, Marya D, Kothari, Smita, Shorr, Andrew F
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717466/ https://www.ncbi.nlm.nih.gov/pubmed/19545361 http://dx.doi.org/10.1186/cc7924

Ejemplares similares

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2010)

Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin
por: Carr, Amy, et al.
Publicado: (2017)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2016)

Very-low-birth-weight infants, prophylactic micafungin or fluconazole
por: Gonzalez-Granado, Luis
Publicado: (2010)

Glutathione Metabolism in Candida albicans Resistant Strains to Fluconazole and Micafungin
por: Maras, Bruno, et al.
Publicado: (2014)

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era
por: Routsi, Christina, et al.
Publicado: (2022)

Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Incidence of candidemia before and after fluconazole prophylaxis implementation in a 14-bed general ICU
por: Vartzeli, P, et al.
Publicado: (2008)

30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study
por: Zilberberg, Marya, et al.
Publicado: (2014)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

1658 C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients
por: Zilberberg, Marya D., et al.
Publicado: (2014)

1455. Epidemiology, Empiric Treatment, and Outcomes Among Hospitalized Patients With Complicated Urinary Tract Infections in the United States, 2013–2018
por: Zilberberg, Marya, et al.
Publicado: (2019)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation
por: Zilberberg, Marya D, et al.
Publicado: (2007)

718 Predictors of Hospital Mortality Among Septic ICU Patients With Acinetobacter spp. Bacteremia: A Cohort Study
por: Shorr, Andrew F., et al.
Publicado: (2014)

Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset Acinetobacter baumannii pneumonia or sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Viruses are prevalent in non-ventilated hospital-acquired pneumonia
por: Shorr, Andrew F., et al.
Publicado: (2017)

Predictors of hospital mortality among septic ICU patients with Acinetobacter spp.bacteremia: a cohort study
por: Shorr, Andrew F, et al.
Publicado: (2014)

Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2021)

The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007
por: Poikonen, Eira, et al.
Publicado: (2010)

Delayed ICU admission with community-acquired severe sepsis greatly increases mortality and resource use
por: Shorr, A, et al.
Publicado: (2011)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
por: De Rosa, Francesco G., et al.
Publicado: (2015)

Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia
por: Tantasuwan, Suchavadee, et al.
Publicado: (2022)

Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Gram-negative resistance and need for ICU among urinary tract infections in the United States
por: Zilberberg, M, et al.
Publicado: (2013)

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience
por: Suh, Jinwoong, et al.
Publicado: (2019)

Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species
por: Sakamoto, Yasutaka, et al.
Publicado: (2021)

2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)

Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
Publicado: (2015)

2259. Predictors of Empiric Carbapenem Therapy in Complicated Intra-Abdominal Infections in the United States, 2013–2017: A Retrospective Cohort Study
por: Zilberberg, Marya, et al.
Publicado: (2019)

Validation of an Empiric Candidemia Treatment Algorithm
por: Stack, Conor M, et al.
Publicado: (2017)

Anemia, costs and mortality in Chronic Obstructive Pulmonary Disease
por: Halpern, Michael T, et al.
Publicado: (2006)

Prolonged acute mechanical ventilation and hospital bed utilization in 2020 in the United States: implications for budgets, plant and personnel planning
por: Zilberberg, Marya D, et al.
Publicado: (2008)

Impact of prior probabilities of MRSA as an infectious agent on the accuracy of the emerging molecular diagnostic tests: a model simulation
por: Zilberberg, Marya D, et al.
Publicado: (2012)

Statistics on steroids: How recognizing competing risks gets us closer to the truth about COVID-19-associated VAP
por: Shorr, Andrew F., et al.
Publicado: (2022)

Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit
por: Pinhati, Henrique Marconi Sampaio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_th46netnq837se1omks9bbhl4r